Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?
Major stressful life events in adulthood and risk of multiple sclerosis.
Relationship between Sustained Disability Progression and Functional System Scores in Relapsing-Remitting Multiple Sclerosis: Analysis of Placebo Data from Four Randomized Clinical Trials.
Management of multiple sclerosis: An overview.
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Neuromuscular taping in multiple sclerosis. A pilot study.
Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark.
In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.
Clonally expanded mitochondrial DNA deletions within the choroid plexus in multiple sclerosis.
Long-term TENS treatment decreases cortical motor representation in multiple sclerosis.
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine.
Pregnancy and Multiple Sclerosis (MS): A Beneficial Association. Possible therapeutic application of embryo-specific Pre-implantation Factor (PIF*).
FDA approves injectable drug to treat opioid-dependent patients
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab.
The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
The histaminergic network in the brain: basic organization and role in disease.
Immune reconstitution inflammatory syndrome mimicking progressive multifocal leucoencephalopathy in a multiple sclerosis patient treated with natalizumab: a case report and review of the literature.
Clinically isolated syndromes and the relationship to multiple sclerosis.
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients
Emerging roles of exosomes in neuron-glia communication.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Response to disease modifying therapies in African Americans with multiple sclerosis.

Pages